Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


5th International Conference and Exhibition on Metabolomics

Osaka, Japan

Tao Wu

Tao Wu

Shanghai University of Traditional Chinese Medicine, China

Title: Serum Lipid Alterations Identified in Chronic Hepatitis B, Hepatitis B Virus-Related Cirrhosis and Carcinoma Patients


Biography: Tao Wu


Backgrounds&Aims: Hepatitis B virus (HBV) is a major pathogenic factor of liver diseases. The incidences of chronic hepatitis B (CHB), HBV-induced cirrhosis and carcinoma are high and increasing. This study aimed to evaluate lipid metabolite changes in the serum that are associated with disease progression from CHB to HBV-induced cirrhosis and to HBV-induced carcinoma. Methods: A targeted metabolomic assay was performed in fasting sera from 136 patients with CHB, 104 patients with HBV-Cirrhosis, and 95 patients with HBV-carcinoma using ultra-performance liquid chromatography triple quadrupole mass spectrometry (UPLC-TQMS). Results: Totally 140 metabolites were identified. A clear separation between HBV-cirrhosis and HBV-carcinoma was obtained using the PLS-DA (partial least squares discriminant analysis) scores of 9 lipid metabolites. Among the 9 metabolites, progressively lower levels of long-chain lysophosphatidylcholines (lysoPC a C18:2, lysoPC a C20:3, lysoPC a C20:4) were observed from CHB to cirrhosis to carcinoma; lower levels of lysoPC a C20:4 were also found in patients with higher Model For End-Stage Liver Disease (MELD Score) in the same disease group; and lysoPC a C20:3 levels were lower in Child-pugh Class C than in Class A and Class B in HBV-Cirrhosis and HBV-Carcinoma patients. Octadecadienylcarnitine(AC C18:2) level was higher in HBV-Cirrhosis patients than in the other two groups. Conclusions: Serum levels of selected long-chain lysoPCs are promising markers for the progression of HBV-induced liver diseases.